State of the Industry — Critical Bio/Pharma Policy Updates for Compliance After COVID | Covington

Stefanie Doebler, Partner at Covington & Burling LLP, kicked off the Pharmaceutical Compliance Congress (PCC) Hybrid Event in September 2021, with a State of the Industry Spotlight Session focused on critical bio/pharma policy updates for compliance after COVID. The session assessed the current state of bio/pharmaceutical companies post-pandemic, evaluated current healthcare policies and rebate rules impacting the industry, and helped navigate drug pricing transparency and reporting on a state and federal level. Watch the full presentation recording below.